Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending April 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), and connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share acquisition transactions.
- Transaction Date: April 10, 2015
- Share Price: 1,625 pence per Ordinary share
- Transaction Type: Acquisitions via dividend re-investment within an ISA
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document solely details minor shareholding adjustments for specific individuals.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is restricted to regulatory disclosure of director share transactions.
Important Facts for Investors
- Directors Sir Andrew Witty, Mr D S Redfern, and Mrs V A Whyte acquired 118, 22, and 19 shares respectively on April 10, 2015.
- Lady C Witty, a connected person of Sir Andrew Witty, acquired 23 shares on the same date.
- All reported acquisitions were executed at a price of 1,625 pence per share.
- The transactions resulted from the re-investment of dividends on shares held within an Individual Savings Account (ISA).